Show simple item record

PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network

dc.contributor.authorSong, Wen-Liang
dc.contributor.authorLinton, MacRae F.
dc.date.accessioned2020-08-27T20:49:24Z
dc.date.available2020-08-27T20:49:24Z
dc.date.issued2019-05-07
dc.identifier.citationChamberlain, A. M., Gong, Y., Shaw, K. M., Bian, J., Song, W. L., Linton, M. F., Fonseca, V., Price-Haywood, E., Guhl, E., King, J. B., Shah, R. U., Puro, J., Shenkman, E., Pawloski, P. A., Margolis, K. L., Hernandez, A. F., & Cooper-DeHoff, R. M. (2019). PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network. Journal of the American Heart Association, 8(9), e011246. https://doi.org/10.1161/JAHA.118.011246en_US
dc.identifier.issn2047-9980
dc.identifier.urihttp://hdl.handle.net/1803/15580
dc.descriptionOnly Vanderbilt University affiliated authors are listed on VUIR. For a full list of authors, access the version of record at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512121/en_US
dc.description.abstractBackground-PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors effectively lower LDL (low-density lipoprotein) cholesterol and have been shown to reduce cardiovascular outcomes in high-risk patients. We used real-world electronic health record data to characterize use of PCSK9 inhibitors, in addition to standard therapies, according to cardiovascular risk status. Methods and Results-Data were obtained from 18 health systems with data marts within the National Patient-Centered Clinical Research Network (PCORnet) using a common data model. Participating sites identified >17.5 million adults, of whom 3.6 million met study criteria. Patients were categorized into 3 groups: (1) dyslipidemia, (2) untreated LDL >= 130 mg/dL, and (3) coronary artery disease or coronary heart disease. Demographics, comorbidities, estimated 10-year atherosclerotic cardiovascular disease risk, and lipid-lowering pharmacotherapies were summarized for each group. Participants' average age was 62 years, 50% were female, and 11% were black. LDL cholesterol ranged from 85 to 151 mg/dL. Among patients in groups 1 and 3, 54% received standard lipid-lowering therapies and a PCSK9 inhibitor was prescribed in <1%. PCSK9 inhibitor prescribing was greatest for patients with coronary artery disease or coronary heart disease and, although prescribing increased during the study period, overall PCSK9 inhibitor prescribing was low. Conclusions-We successfully used electronic health record data from 18 PCORnet data marts to identify >3.6 million patients meeting criteria for 3 patient groups. Approximately half of patients had been prescribed lipid-lowering medication, but <1% were prescribed PCSK9 inhibitors. PCSK9 inhibitor prescribing increased over time for patients with coronary artery disease or coronary heart disease but not for those with dyslipidemia.en_US
dc.description.sponsorshipThis study was funded by the Patient-Centered Outcomes Research Institute (PCORI) Award (CDRN-1501-26692 contract amendment). The statements presented in this publication are solely the responsibility of the authors and do not necessarily represent the views of PCORI, its board of governors, or its methodology committee.en_US
dc.language.isoen_USen_US
dc.publisherJournal of the American Heart Associationen_US
dc.rightsCopyright © 2019 The Authors and Mayo Clinic. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
dc.source.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512121/
dc.subjectoronary artery diseaseen_US
dc.subjectlipidsen_US
dc.subjectPCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitoren_US
dc.subjectsecondary preventionen_US
dc.titlePCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Networken_US
dc.typeArticleen_US
dc.identifier.doi10.1161/JAHA.118.011246


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record